Skip to main content
Log in

Lymphocytopenia is associated with an increased risk of severe infections in patients with multiple myeloma treated with bortezomib-based regimens

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Bortezomib is a proteasome inhibitor with potent antimyeloma activity in relapsed/refractory multiple myeloma (MM) patients. We evaluated the types and factors affecting the onset of infectious complications and mortality owing to infection in MM patients treated with bortezomib-based regimens. We reviewed 139 patients with MM treated with regimens containing bortezomib in order to assess the types and factors affecting the development of severe infections. Infections occurred in 56 (40.3 %) of 139 patients and 83 (7.8 %) cases of the 1,069 evaluable cycles. Severe infections developed in 43 (30.9 %) patients and ten patients (7.1 %) died during bortezomib-based treatment. Multivariate analysis determined lymphocytopenia grade 3–4 (OR 3.17, 95 % CI 1.38–7.31, P = 0.007) and number of cycles ≤8 (OR 3.91, 95 % CI 1.39–11.02, P = 0.010) as risk factors associated with increased severe infection. This study showed that MM patients who received bortezomib-based regimens are at a higher risk of severe infections within eight cycles of treatment during especially severe lymphocytopenic periods. MM patients treated with bortezomib-based regimens should be closely monitored for the development of infectious complications during lymphocytopenia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kristinsson SY, Landgren O, Dickman PW, Derolf AR, Bjorkholm M. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol. 2007;25:1993–9.

    Article  PubMed  Google Scholar 

  2. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood. 2008;111:2521–6.

    Article  PubMed  CAS  Google Scholar 

  3. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516–20.

    Article  PubMed  CAS  Google Scholar 

  4. Augustson BM, Begum G, Dunn JA, Barth NJ, Davies F, Morgan G, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002—Medical Research Council Adult Leukaemia Working Party. J Clin Oncol. 2005;23:9219–26.

    Article  PubMed  Google Scholar 

  5. Fahey JL, Scoggins R, Utz JP, Szwed CF. Infection, antibody response and gamma globulin components in multiple myeloma and macroglobulinemia. Am J Med. 1963;35:698–707.

    Article  PubMed  CAS  Google Scholar 

  6. Nucci M, Anaissie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis. 2009;49:1211–25.

    Article  PubMed  CAS  Google Scholar 

  7. Oken MM, Pomeroy C, Weisdorf D, Bennett JM. Prophylactic antibiotics for the prevention of early infection in multiple myeloma. Am J Med. 1996;100:624–8.

    Article  PubMed  CAS  Google Scholar 

  8. Gracia Escudero A, Martin Gonzalez M, Gimenez Garrido F, Clavero Farre C, Garcia Perez MJ, Alvarez Corral G, et al. A prospective, controlled, non-randomized study of three cohorts to test the effectiveness of two antibiotics levofloxacin and cotrimoxazol on antibacterial prophylaxis in neutropenic patients. Med Clin (Barc) 2003;120:321–25.

    Google Scholar 

  9. Kim YK, Sohn SK, Lee JH, Yang DH, Moon JH, Ahn JS, et al. Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study. Ann Hematol. 2010;89:475–82.

    Article  PubMed  CAS  Google Scholar 

  10. Kim SJ, Kim K, Do YR, Bae SH, Yang DH, Lee JJ. Low-dose acyclovir is effective for prevention of herpes zoster in myeloma patients treated with bortezomib: a report from the Korean Multiple Myeloma Working Party (KMMWP) Retrospective Study. Jpn J Clin Oncol. 2011;41:353–7.

    Article  PubMed  Google Scholar 

  11. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351:1860–73.

    Article  PubMed  CAS  Google Scholar 

  12. Matsumoto M, Yamada T, Yoshinaga SK, Boone T, Horan T, Fujita S, et al. Essential role of NF-kappa B-inducing kinase in T cell activation through the TCR/CD3 pathway. J Immunol. 2002;169:1151–8.

    PubMed  CAS  Google Scholar 

  13. Shah JJ, Orlowski RZ. Proteasome inhibitors in the treatment of multiple myeloma. Leukemia. 2009;23:1964–79.

    Article  PubMed  CAS  Google Scholar 

  14. Berges C, Haberstock H, Fuchs D, Miltz M, Sadeghi M, Opelz G, et al. Proteasome inhibition suppresses essential immune functions of human CD4+ T cells. Immunology. 2008;124:234–46.

    Article  PubMed  CAS  Google Scholar 

  15. Cerundolo V, Benham A, Braud V, Mukherjee S, Gould K, Macino B, et al. The proteasome-specific inhibitor lactacystin blocks presentation of cytotoxic T lymphocyte epitopes in human and murine cells. Eur J Immunol. 1997;27:336–41.

    Article  PubMed  CAS  Google Scholar 

  16. Basler M, Lauer C, Beck U, Groettrup M. The proteasome inhibitor bortezomib enhances the susceptibility to viral infection. J Immunol. 2009;183:6145–50.

    Article  PubMed  CAS  Google Scholar 

  17. Haslett PA, Hanekom WA, Muller G, Kaplan G. Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro. J Infect Dis. 2003;187:946–55.

    Article  PubMed  CAS  Google Scholar 

  18. Haslett PA, Corral LG, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med. 1998;187:1885–92.

    Article  PubMed  CAS  Google Scholar 

  19. Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet. 2006;367:825–31.

    Article  PubMed  CAS  Google Scholar 

  20. Cesana C, Nosari AM, Klersy C, Miqueleiz S, Rossi V, Ferrando P, et al. Risk factors for the development of bacterial infections in multiple myeloma treated with two different vincristine–adriamycin–dexamethasone schedules. Haematologica. 2003;88:1022–8.

    PubMed  Google Scholar 

  21. Offidani M, Corvatta L, Polloni C, Gentili S, Brioni A, Visani G, et al. Infectious complications in patients with multiple myeloma treated with new drug combinations containing thalidomide. Leuk Lymphoma. 2011;52:776–85.

    Article  PubMed  CAS  Google Scholar 

  22. Ljungman P, de la Camara R, Perez-Bercoff L, Abecasis M, Nieto Campuzano JB, Cannata-Ortiz MJ, et al. Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients. Haematologica. 2011;96:1231–5.

    Article  PubMed  Google Scholar 

  23. Ljungman P, Ward KN, Crooks BN, Parker A, Martino R, Shaw PJ, et al. Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transpl. 2001;28:479–84.

    Article  CAS  Google Scholar 

  24. Wyllie DH, Bowler IC, Peto TE. Relation between lymphopenia and bacteraemia in UK adults with medical emergencies. J Clin Pathol. 2004;57:950–5.

    Article  PubMed  CAS  Google Scholar 

  25. Ng WL, Chu CM, Wu AK, Cheng VC, Yuen KY. Lymphopenia at presentation is associated with increased risk of infections in patients with systemic lupus erythematosus. QJM. 2006;99:37–47.

    Article  PubMed  CAS  Google Scholar 

  26. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609–17.

    Article  PubMed  CAS  Google Scholar 

  27. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359:906–17.

    Google Scholar 

  28. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487–98.

    Article  PubMed  CAS  Google Scholar 

  29. Mateos MV, Richardson PG, Schlag R, Khuaqeva NK, Dimopoulos MA, Shpilberq O, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol. 2010;28:2259–66.

    Article  PubMed  CAS  Google Scholar 

  30. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticoids. Rev Infect Dis. 1989;11:954–63.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Je-Jung Lee.

Additional information

S.-H. Jung and S.-Y. Bae contributed equally to this work.

About this article

Cite this article

Jung, SH., Bae, SY., Ahn, JS. et al. Lymphocytopenia is associated with an increased risk of severe infections in patients with multiple myeloma treated with bortezomib-based regimens. Int J Hematol 97, 382–387 (2013). https://doi.org/10.1007/s12185-013-1270-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-013-1270-7

Keywords

Navigation